Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Change in Acquisitions & Divestments (2023 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Change in Acquisitions & Divestments for 3 consecutive years, with $15.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Acquisitions & Divestments rose 202.19% year-over-year to $15.9 million, compared with a TTM value of $70.0 million through Sep 2025, up 428.24%, and an annual FY2024 reading of $26.4 million, up 1222.5% over the prior year.
  • Change in Acquisitions & Divestments was $15.9 million for Q3 2025 at X4 Pharmaceuticals, down from $28.2 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $28.2 million in Q2 2025 and bottomed at $1.0 million in Q3 2023.
  • Average Change in Acquisitions & Divestments over 3 years is $9.4 million, with a median of $5.2 million recorded in 2024.
  • The sharpest move saw Change in Acquisitions & Divestments surged 1320.0% in 2024, then skyrocketed 135.0% in 2025.
  • Year by year, Change in Acquisitions & Divestments stood at $1.0 million in 2023, then soared by 1320.0% to $14.2 million in 2024, then rose by 11.73% to $15.9 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for XFOR at $15.9 million in Q3 2025, $28.2 million in Q2 2025, and $11.8 million in Q1 2025.